Elia G
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Clin Ter. 2018 Nov-Dec;169(6):e303-e307. doi: 10.7417/CT.2018.2098.
The importance of the Type-1 helper immune response in the development of Vitiligo (Vit), and of chemokine receptor (CXCR)3 receptor and its chemokine monokine induced by interferon (IFN)-γ(MIG) has been shown by several studies. MIG/ interferon (IFN)-γ-inducible protein 10 (IP10) /CXCR3 axis mediated T-cell recruitment into the skin in Vit is an early event in the progression of the disease. MIG and IP10 circulating levels are increased in progressive Vit. It has been suggested that MIG and CXCR3 could be novel targets of future therapeutical approaches. Other studies have suggested that measuring MIG directly in the skin might be effective in clinical trials as an early marker of treatment response. Further studies are needed to explore the use of new molecules that act as antagonists of CXCR3, or block MIG, in Vit in a clinical setting.
多项研究表明，1型辅助性免疫反应在白癜风（Vit）发展过程中的重要性，以及趋化因子受体（CXCR）3及其由干扰素（IFN）-γ诱导的趋化因子单核细胞趋化蛋白诱导蛋白10（MIG）的重要性。MIG/干扰素（IFN）-γ诱导蛋白10（IP10）/CXCR3轴介导T细胞募集至Vit患者的皮肤中，这是该疾病进展过程中的早期事件。进展期Vit患者的MIG和IP10循环水平升高。有人提出，MIG和CXCR3可能是未来治疗方法的新靶点。其他研究表明，在皮肤中直接检测MIG可能在临床试验中作为治疗反应的早期标志物有效。需要进一步研究以探索在临床环境中使用作为CXCR3拮抗剂或阻断MIG的新分子治疗Vit的方法。
